Sensus Healthcare, Inc. (SRTS) Reports Q1 Loss, Tops Revenue Estimates
Sensus Healthcare, Inc. (SRTS) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of $0.04. This compares to earnings of $0.14 per share a year ago.
Sensus Healthcare, Inc. (SRTS) Stock Falls Amid Market Uptick: What Investors Need to Know
In the latest trading session, Sensus Healthcare, Inc. (SRTS) closed at $4.22, marking a -0.47% move from the previous day.
Earnings Preview: Sensus Healthcare, Inc. (SRTS) Q1 Earnings Expected to Decline
Sensus Healthcare (SRTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Sensus Healthcare (SRTS) a Buy as Wall Street Analysts Look Optimistic?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Sensus Healthcare, Inc. (SRTS) Rises Yet Lags Behind Market: Some Facts Worth Knowing
In the latest trading session, Sensus Healthcare, Inc. (SRTS) closed at $4.69, marking a +1.3% move from the previous day.
Sensus Healthcare, Inc. (SRTS) Increases Despite Market Slip: Here's What You Need to Know
Sensus Healthcare, Inc. (SRTS) reachead $4.48 at the closing of the latest trading day, reflecting a +0.45% change compared to its last close.
Sensus Healthcare, Inc. (SRTS) Rises As Market Takes a Dip: Key Facts
Sensus Healthcare, Inc. (SRTS) closed the most recent trading day at $4.69, moving +1.08% from the previous trading session.
Here's Why Sensus Healthcare, Inc. (SRTS) Gained But Lagged the Market Today
Sensus Healthcare, Inc. (SRTS) closed the most recent trading day at $4.78, moving +0.84% from the previous trading session.
Brokers Suggest Investing in Sensus Healthcare (SRTS): Read This Before Placing a Bet
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Sensus Healthcare: A Tough Q1 2025 Awaits Ahead
Q4 2024 showed a significant miss in profitability despite a 4% YoY sales growth; gross profit margin dropped due to a one-time discount for a new big client. The FDA initiatives are interesting, but they will bring a slowdown in sales as they are fully rolled out. Management has warned of a Q1 2025 with considerably lower sales due to the Fair Deal Agreements and seasonal factors.
Sensus Healthcare, Inc. (SRTS) Q4 2024 Earnings Call Transcript
Sensus Healthcare, Inc. (NASDAQ:SRTS ) Q4 2024 Earnings Conference Call February 5, 2025 4:30 PM ET Company Participants Tirth Patel - Alliance Advisors, IR Joe Sardano - Chairman and CEO Michael Sardano - President & General Counsel Javier Rampolla - CFO Conference Call Participants Jeremy Pearlman - Maxim Group Arsalan Cameron - Roth Capital Partners Ben Haynor - Lake Street Capital Markets Operator Good day, and welcome to the Sensus Healthcare Fourth Quarter 2024 Financial Results Conference Call. [Operator Instructions].
Sensus Healthcare, Inc. (SRTS) Lags Q4 Earnings Estimates
Sensus Healthcare, Inc. (SRTS) came out with quarterly earnings of $0.09 per share, missing the Zacks Consensus Estimate of $0.10 per share. This compares to earnings of $0.26 per share a year ago.
